Trials / Completed
CompletedNCT02985190
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Groupe Francophone des Myelodysplasies · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase II of effcicacy and tolerance of azacitidine in patients with myelodysplatic syndrome and steroid dependent or resistent systemic auto-immune and inflammatory disorders
Detailed description
This trial will be a prospective French nationwide study analyzing the effect of treatment with azacitidine in patients with MDS-associated SAID with steroid dependence and/or resistance, and its correlation with possible changes in immunological parameters
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacitidine | Azacitidine at 75mg/m²/j for 7 days. |
Timeline
- Start date
- 2017-01-26
- Primary completion
- 2021-09-02
- Completion
- 2022-08-30
- First posted
- 2016-12-07
- Last updated
- 2022-10-04
Locations
59 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02985190. Inclusion in this directory is not an endorsement.